Techno-Science on MSN6d
🧬 The secret of ovum-sperm fusion finally revealed thanks to AIThe fusion of an ovum and a sperm relies on processes that remain largely unknown. But today, researchers have identified a ...
Interesting Engineering on MSN1mon
Defeating AIDS: MIT reveals new vaccination method that could kill HIV in just two shotsOne promising vaccine now in clinical trials consists of an HIV protein called an envelope trimer and a nanoparticle called ...
Most other HIV vaccine formulations use a single HIV Env protein as the immunogen which has different surfaces available that can distract the immune system from making antibodies binding the Env ...
Clover announces positive clinical data for RSV vaccine candidate SCB-1019 compared head-to-head versus GSK’s Arexvy: Shanghai Wednesday, October 30, 2024, 17:00 Hrs [IST] Clove ...
想象一下，当你走在街头，看到一片绿意盎然的草地，其中夹杂着几朵小小的三叶草。这些不起眼的小植物却可能蕴藏着改变世界的秘密。同样地，三叶草生物制药有限公司也是一家看似平凡但实则充满潜力的企业。它专注于开发新型疫苗及生物治疗候选产品，旨在解决全球最危及生命的疾病及公共卫生威胁。
Under certain conditions, SOD1 will change its shape and reassemble itself into a three-unit form called a trimer. "We need to understand how the SOD1 trimers kill cells and the mechanisms ...
你是否曾经好奇过，为什么我们每年都要接种流感疫苗？而如今，一种新的呼吸道合胞病毒（RSV）疫苗正在悄然改变这一现状。最近，三叶草生物-B(02197.HK)宣布其二价RSV候选疫苗SCB-1019在与GSK的AREXVY疫苗进行头对头比较时，取得了令人瞩目的积极结果。这究竟意味着什么？让我们一起揭开这个谜底。 想象一下，在一个寒冷的冬日，你的孩子突然开始咳嗽、发烧，医生告诉你这是RSV感染。这种病 ...
全球首家公布RSV候选疫苗与已获批重磅RSV疫苗头对头临床试验结果、且结果积极的厂家，来自中国。当开年至今无一款国产创新型疫苗获批上市，二类疫苗又几乎迎来全员内卷、“价格战”四处打响时，中国创新疫苗行业终于传来了一则好消息：一款国产呼吸道合胞病毒（R ...
【财华社讯】三叶草生物-B (02197.HK)公布，在Ⅰ期临床试验中评估未使用佐剂的二价RSV PreF-三聚体亚单位候选疫苗SCB-1019 ...
当前正是第三季度财报季，中国疫苗行业在当前经济周期波动下业绩承压，以往热卖的疫苗大品种也在面临国内市场进一步降价竞争的挑战。作为生物医药细分赛道的国产创新疫苗行业，如何寻找到一条破局企稳，拨云见日的路径，是决定各国产疫苗厂家未来商业生死的核心战略考量 ...
智通财经APP获悉，三叶草生物-B (02197)涨超14%，截至发稿，涨14.75%，报0.35港元，成交额83.56万港元。 消息面上，三叶草生物今早宣布，其在Ⅰ期临床试验中评估未使用佐剂的二价RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback